CDPQ investment in Sanfer : Mexican pharma company Sanfer has secured a $500 million minority investment from Canadian long-term institutional investor Caisse de dépôt et placement du Québec (CDPQ) to help it execute its continued expansion plans across Mexico and the Latin American region.
In the last 20 years, Sanfer claims to have closed more than 100 brand acquisitions, acquired eight pharma companies and launched 100+ new products in Mexico and Latin America.
The Mexican pharma company plans to use the new capital to speed up its growth by means of organic and through further acquisitions, throughout the region.
Commenting on CDPQ investment in Sanfer, Ricardo Amtmann A – Chairman and CEO of Sanfer, said: “The addition of CDPQ as a strategic partner marks an important moment for Sanfer as we look to further strengthen our position across Mexico and Latin America.
“CDPQ, together with our existing partner General Atlantic, will contribute invaluable expertise as we pursue strategic growth opportunities that will allow Sanfer to meaningfully scale the business and deepen our reach with customers. We are honored to have CDPQ’s trust in our Company and to see their commitment to the Latin American region.”
General Atlantic, which is a global growth equity firm, will hold on to a significant minority stake in Sanfer.
Stephane Etroy – Executive Vice-President and Head of Private Equity at CDPQ, commenting on CDPQ investment in Sanfer, said: “Our partnership with Sanfer is an opportunity for us to grow our exposure to targeted countries in Latin America, while investing in a key sector of these economies.
“We are proud to be partnering with a company of Sanfer’s caliber, alongside General Atlantic. We are confident in the pharmaceutical industry’s long-term outlook and look forward to working with Sanfer’s leadership team to capitalize on growth opportunities.”
CDPQ investment in Sanfer, which will be subject to customary regulatory approvals, is expected to be closed later this year.